Table of Contents
ISRN Hematology
Volume 2011 (2011), Article ID 108397, 6 pages
http://dx.doi.org/10.5402/2011/108397
Review Article

Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents

Department of Hematology, Uppsala University Hospital, 751 85 Uppsala, Sweden

Received 5 June 2011; Accepted 25 July 2011

Academic Editors: L. Catalano and H.-M. Tsai

Copyright © 2011 Torbjörn Karlsson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Eschbach, M. Kelly, N. Haley, R. Abels, and J. Adamson, “Treatment of the anemia of progressive renal failure with recombinant human erythropoietin,” New England Journal of Medicine, vol. 321, no. 3, pp. 158–163, 1989. View at Google Scholar · View at Scopus
  2. R. I. Abels, “Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer,” Seminars in Oncology, vol. 19, no. 3, supplement 8, pp. 29–35, 1992. View at Google Scholar · View at Scopus
  3. J. L. Spivak, “The application of recombinant erythropoietin in anemic patients with cancer,” Seminars in Oncology, vol. 19, no. 3, supplement 8, pp. 25–28, 1992. View at Google Scholar · View at Scopus
  4. H. Ludwig, E. Fritz, H. Kotzmann, P. Hocker, H. Gisslinger, and U. Barnas, “Erythropoietin treatment of anemia associated with multiple myeloma,” New England Journal of Medicine, vol. 322, no. 24, pp. 1693–1699, 1990. View at Google Scholar · View at Scopus
  5. M. Cazzola, D. Messinger, V. Battistel et al., “Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response,” Blood, vol. 86, no. 12, pp. 4446–4453, 1995. View at Google Scholar · View at Scopus
  6. A. Österborg, M. A. Boogaerts, R. Cimino et al., “Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study,” Blood, vol. 87, no. 7, pp. 2675–2682, 1996. View at Google Scholar · View at Scopus
  7. G. D. Demetri, M. Kris, J. Wade, L. Degos, and D. Cella, “Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3412–3425, 1998. View at Google Scholar · View at Scopus
  8. M. R. Nowrousian, “Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours,” Medical Oncology, vol. 15, no. 1, pp. S19–S28, 1998. View at Google Scholar · View at Scopus
  9. J. Vansteenkiste, R. Pirker, B. Massuti et al., “Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy,” Journal of the National Cancer Institute, vol. 94, no. 16, pp. 1211–1220, 2002. View at Google Scholar · View at Scopus
  10. M. Hedenus, M. Adriansson, J. San Miguel et al., “Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study,” British Journal of Haematology, vol. 122, no. 3, pp. 394–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Ichinose, T. Seto, Y. Nishiwaki et al., “Randomized phase 2 dose-finding study of weekly administration of darbepoetin alfa in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy,” Japanese Journal of Clinical Oncology, vol. 40, no. 6, pp. 521–529, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. N. Roy and N. C. Andrews, “Anemia of inflammation: the hepcidin link,” Current Opinion in Hematology, vol. 12, no. 2, pp. 107–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Nemeth and T. Ganz, “Hepcidin and iron-loading anemias,” Haematologica, vol. 91, no. 6, pp. 727–732, 2006. View at Google Scholar · View at Scopus
  14. E. Nemeth, S. Rivera, V. Gabayan et al., “IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin,” Journal of Clinical Investigation, vol. 113, no. 9, pp. 1271–1276, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Nemeth, M. S. Tuttle, J. Powelson et al., “Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization,” Science, vol. 306, no. 5704, pp. 2090–2093, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Viatte, G. Nicolas, D. Q. Lou et al., “Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice,” Blood, vol. 107, no. 7, pp. 2952–2958, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Rivera, L. Liu, E. Nemeth, V. Gabayan, O. E. Sorensen, and T. Ganz, “Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia,” Blood, vol. 105, no. 4, pp. 1797–1802, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. D. A. Weinstein, C. N. Roy, M. D. Fleming, M. F. Loda, J. I. Wolfsdorf, and N. C. Andrews, “Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease,” Blood, vol. 100, no. 10, pp. 3776–3781, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Locatelli, P. Barany, B. Canaud et al., “European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure,” Nephrology Dialysis Transplantation, vol. 19, supplement 2, pp. 1–47, 2004. View at Google Scholar
  20. G. Mirescu, L. Garneata, C. Capusa, and N. Ursea, “Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients,” Nephrology Dialysis Transplantation, vol. 21, no. 1, pp. 120–124, 2006. View at Google Scholar
  21. D. H. Henry, “Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO?” Oncologist, vol. 3, no. 4, pp. 275–278, 1998. View at Google Scholar · View at Scopus
  22. M. Woorwood, “Laboratory determination of iron status,” in Iron Metabolism in Health and Disease, J. Brock, J. Halliday, M. Pippard, and L. Powell, Eds., pp. 449–476, W. B. Saunders, London. UK, 1994. View at Google Scholar
  23. A. N. Baer, E. N. Dessypris, and S. B. Krantz, “The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis,” Seminars in Arthritis and Rheumatism, vol. 19, no. 4, pp. 209–223, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. Rizzo, M. Brouwers, P. Hurley et al., “American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer,” Blood, vol. 116, no. 20, pp. 4045–4059, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. S. Aapro and H. Link, “September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents,” Oncologist, vol. 13, no. 3, pp. 33–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Auerbach, H. Ballard, J. R. Trout et al., “Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1301–1307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufmane, “Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy,” Oncologist, vol. 12, no. 2, pp. 231–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Hedenus, G. Birgegård, P. Näsman et al., “Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies,” Leukemia, vol. 21, no. 4, pp. 627–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Bastit, A. Vandebroek, S. Altintas et al., “Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in subjects with chemotherapy-induced anemia,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1611–1618, 2008. View at Google Scholar
  30. P. Pedrazzoli, A. Farris, S. Del Prete et al., “Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1619–1625, 2008. View at Google Scholar
  31. M. Auerbach, P. T. Silberstein, R. T. Webb et al., “Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia,” American Journal of Hematology, vol. 85, no. 9, pp. 655–663, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Steensma, J. Sloan, S. Dakhil et al., “Phase III randomized study of the effect of parenteral iron, no iron, or oral iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia,” Journal of Clinical Oncology, vol. 29, no. 1, pp. 97–105, 2011. View at Google Scholar
  33. S. Fishbane, G. L. Frei, and J. Maesaka, “Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation,” American Journal of Kidney Diseases, vol. 26, no. 1, pp. 41–46, 1995. View at Google Scholar · View at Scopus
  34. I. C. Macdougall, B. Tucker, J. Thompson, C. R. V. Tomson, L. R. I. Baker, and A. E. G. Raine, “A randomized controlled study of iron supplementation in patients treated with erythropoietin,” Kidney International, vol. 50, no. 5, pp. 1694–1699, 1996. View at Google Scholar · View at Scopus
  35. M. Auerbach, “Intravenous iron failed to improve erythropoietic response in patients with chemotherapy-induced anemia,” 2010, http://www.hemonctoday.com/article.aspx?rid=78461.
  36. R. Agarwal, “Nonhematological benefits of iron,” American Journal of Nephrology, vol. 27, no. 6, pp. 565–571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Fishbane, V. D. Ungureanu, J. K. Maesaka, C. J. Kaupke, V. Lim, and J. Wish, “The safety of intravenous iron dextran in hemodialysis patients,” American Journal of Kidney Diseases, vol. 28, no. 4, pp. 529–534, 1996. View at Google Scholar · View at Scopus
  38. G. R. Bailie, J. A. Clark, C. E. Lane, and P. L. Lane, “Hypersensitivity reactions and deaths associated with intravenous iron preparations,” Nephrology Dialysis Transplantation, vol. 20, no. 7, pp. 1443–1449, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. S. B. Silverstein and G. M. Rodgers, “Parenteral iron therapy options,” American Journal of Hematology, vol. 76, no. 1, pp. 74–78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Kessler, B. Hoen, D. Mayeux, D. Hestin, and C. Fontenaille, “Bacteremia in patients on chronic hemodialysis: a multicenter prospective survey,” Nephron, vol. 64, no. 1, pp. 95–100, 1993. View at Google Scholar · View at Scopus
  41. B. Hoen, M. Kessler, D. Hestin, and D. Mayeux, “Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey,” Nephrology Dialysis Transplantation, vol. 10, no. 3, pp. 377–381, 1995. View at Google Scholar · View at Scopus
  42. B. Hoen, A. Paul-Dauphin, D. Hestin, and M. Kessler, “EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients,” Journal of the American Society of Nephrology, vol. 9, no. 5, pp. 869–876, 1998. View at Google Scholar · View at Scopus
  43. R. Agarwal, N. Vasavada, N. G. Sachs, and S. Chase, “Oxidative stress and renal injury with intravenous iron-in patients with chronic kidney disease,” Kidney International, vol. 65, no. 6, pp. 2279–2289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Drüeke, V. Witko-Sarsat, Z. Massy et al., “Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease,” Circulation, vol. 106, no. 17, pp. 2212–2217, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. A. K. Salahudeen, B. Oliver, J. D. Bower, and L. J. Roberts, “Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis,” Kidney International, vol. 60, no. 4, pp. 1525–1531, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Schaller, B. Scheiber-Mojdehkar, M. Woltz et al., “Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients,” Kidney International, vol. 68, no. 6, pp. 2814–2822, 2005. View at Google Scholar
  47. J. Toblli, G. Cao, L. Olivieri, and M. Angerosa, “Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds,” Nephrology Dialysis Transplantation, vol. 25, no. 11, pp. 3631–3640, 2010. View at Google Scholar
  48. L. Lin, E. V. Valore, E. Nemeth, J. B. Goodnough, V. Gabayan, and T. Ganz, “Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4,” Blood, vol. 110, no. 6, pp. 2182–2189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. B. G. Danielson, “Structure, chemistry, and pharmacokinetics of intravenous iron agents,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. S93–S98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Beshara, J. Sörensen, M. Lubberink et al., “Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography,” British Journal of Haematology, vol. 120, no. 5, pp. 853–859, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. D. B. Van Wyck, J. Anderson, and K. Johnson, “Labile iron in parenteral iron formulations: a quantitative and comparative study,” Nephrology Dialysis Transplantation, vol. 19, no. 3, pp. 561–565, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Bellet, H. Ghazal, M. Flam et al., “A phase III randomized controlled study comparing iron sucrose intravenously (iv) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy,” Journal of Clinical Oncology, vol. 25, no. 18, p. 9109, 2007. View at Google Scholar
  53. Y. Beguin, J. Maertens, B. De Prijck et al., “Darbepoetin-alfa and i.v. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter tial,” Blood, vol. 112, no. 11, abstract 54, 2008. View at Google Scholar
  54. A. Gafter-Gvili, B. Rosen-Zvi, L. Vidal, U. Gafter, J. Vansteenkiste, and O. Shpilberg, “Intravenous iron supplementation for the treatment of cancer-related anemia-systematic review and meta-analysis,” Blood, vol. 116, no. 21, abstract 4249, 2010. View at Google Scholar
  55. R. Mhaskar, H. Wao, A. Kumar, B. Miladinovic, and B. Djulbegovic, “Role of iron supplementation to erythropoiesis stimulating agents in the management of chemptherapy-induced anemia in cancer patients: a systematic review and meta-analysis,” Blood, vol. 116, no. 21, abstract 2055, 2010. View at Google Scholar